Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Hepatitis Clear all
Terminated Not applicable Interventional Results available

Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis

NCT01922895
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Lactobacillus Rhamnosus GG, Placebo for Probiotic
Dietary Supplement · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Louisville, Kentucky • Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 25, 2026, 5:13 PM EDT
Terminated Phase 3 Interventional Results available

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

NCT02612428
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD System, Standard of Care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Coronado, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 25, 2026, 5:13 PM EDT
Completed No phase listed Observational

Outcomes Using MARS for Patients With ALF

NCT05594953
View directory record Official record
Conditions
Alcoholic Hepatitis, Acute Liver Failure
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 25, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

NCT03452540
View directory record Official record
Conditions
Severe Acute Decompensated Alcoholic Hepatitis
Interventions
1000mg DS102 (BID)
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Miami, Florida • Kansas City, Kansas • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Results available

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

NCT02128217
View directory record Official record
Conditions
HIV-1 Infection, Hepatitis
Interventions
Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 25, 2026, 5:13 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 25, 2026, 5:13 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Cardiox Liver Function Test Pivotal Trial

NCT02552901
View directory record Official record
Conditions
Hepatic Failure, Liver Failure
Interventions
0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
Drug
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

NCT01471028
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD treatment, Standard of care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis

NCT00973817
View directory record Official record
Conditions
Acute On Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 2 Interventional

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 25, 2026, 5:13 PM EDT
Completed No phase listed Observational

Collection of Liver Tissue for Virologic Studies

NCT00005936
View directory record Official record
Conditions
Virus Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 4 Interventional

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

NCT00194480
View directory record Official record
Conditions
Substance-Related Disorders, Hepatitis
Interventions
Pegylated Interferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
15 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 25, 2026, 5:13 PM EDT
Completed No phase listed Observational

Collections of Blood and Stool Samples in Patients With Acute Hepatitis

NCT00001879
View directory record Official record
Conditions
Hepatitis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 25, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

NCT01937130
View directory record Official record
Conditions
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Results available

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

NCT00962871
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys], tenofovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

NCT03432260
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 25, 2026, 5:13 PM EDT
Approved For Marketing No phase listed Expanded access

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

NCT01198860
View directory record Official record
Conditions
CHRONIC HEPATITIS B
Interventions
CTH Chronic Hepatitis B
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 25, 2026, 5:13 PM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

NCT04903626
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir (GLE/PIB)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 25, 2026, 5:13 PM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 25, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 5:13 PM EDT
Completed Phase 1Phase 2 Interventional

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

NCT00771446
View directory record Official record
Conditions
Acute Hepatitis, Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
19 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 25, 2026, 5:13 PM EDT